Challenges of Weight Loss Medication Adherence and Insurance Coverage
High patient out-of-pocket costs and side effects are significant factors contributing to the discontinuation of weight loss medications. A recent review published in the British Medical Journal highlighted that approximately 50% of individuals who start on weight loss drugs stop taking them within one year, leading to a return to baseline weight in an average of 1.7 years.
Aside from weight regain, stopping GLP-1 medications also results in the reversal of positive effects such as reduced cardiovascular risk, lower blood sugar, cholesterol, and blood pressure levels. This reversal is more substantial than what occurs when individuals stop behavioral weight loss programs.
Another study involving over 96,000 patients initiating GLP-1s found that 46% of patients with diabetes and 65% without diabetes discontinued the drugs within one year. Despite this, about 1 in 8 adults in the U.S. are currently taking GLP-1 medications for weight loss or other conditions.
Insurance coverage for obesity medications, including GLP-1s, has been limited due to high costs. Medicaid programs in several states, including California’s MediCal, have recently ended coverage for weight loss drugs. Lack of patient adherence and persistence on these medications has led insurers to avoid covering them or to discontinue coverage over time.
Side effects, such as gastrointestinal problems, and high out-of-pocket costs due to lack of insurance coverage are primary reasons for discontinuation. Manufacturers have introduced direct-to-consumer programs to make these medications more affordable, but affordability remains a challenge for many individuals.
President Trump announced agreements with drug manufacturers to lower the price of certain obesity drugs on an online platform, offering discounts on medications like Zepbound and Wegovy. Despite these efforts, many patients still find these medications unaffordable, leading to continued challenges in insurance coverage.
The recent launch of an oral pill version of Wegovy may offer convenience and lower prices, potentially increasing medication adherence. However, the impact on insurance coverage remains uncertain.
